A variety of CCK anti-obesity drugs in early clinical development have failed to progress in later clinical trials presumably in part because of a lack of efficacy beyond an initial reduction in hunger. The gene discussed is CCK; the disease is obesity due to melanocortin 4 receptor deficiency.